It is clear to all of us that Acadia / Neuren's initiative to suspend Trofinetide due to Covid19 is part of a small percentage compared to all the other trials of all kinds that have not been suspended, including those that most resemble us.in recent years, I have witnessed some cases in which FDA has approved drugs for unsatisfied therapies even in phase 2, in the context in which they already showed absence of toxicity accompanied by a fair efficacy, essentially what Neuren has already shown in its phase 2.what I suspect and which in the light of the facts now I argue is that the suspension of Trofinetide for Covid 19 is a strategy to arrive at an early approval by the FDA. there is no doubt that we already have all the requirements to obtain it and I am referring to the granting of Priority Review, Orphan Drug and Rare Pediatric Disease.this is the last case of mid-April last to make a serious reflection. Phase 2 trial, suspended for Covid 19 and approved by the FDA for the requirements of which Trofinetide is in full compliance. following the links on which to consult.
https://www.prnewswire.com/news-releases/fda-approves-first-therapy-for-children-with-debilitating-and-disfiguring-rare-disease-301038879.html
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-children-debilitating-and-disfiguring-rare-disease
https://finance.yahoo.com/news/astrazenecas-koselugo-gets-fda-nod-161704243.html
https://clinicaltrials.gov/ct2/show/NCT03213691?term=Koselugo&draw=2&rank=1
lastly, I would like to point out that the positive rebound from the 1 dollar fund matured in the days of April of the news that I posted.
- Forums
- ASX - By Stock
- NEU
- ACADIA TALKS TROFINETIDE
ACADIA TALKS TROFINETIDE, page-65
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B |
Open | High | Low | Value | Volume |
$13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3816 | $13.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.78 | 2834 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 13.620 |
2 | 733 | 13.510 |
7 | 9120 | 13.500 |
1 | 1000 | 13.480 |
1 | 50 | 13.420 |
Price($) | Vol. | No. |
---|---|---|
13.960 | 2652 | 1 |
14.000 | 6595 | 2 |
14.110 | 1000 | 1 |
14.120 | 493 | 1 |
14.250 | 1000 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online